| Candida Goehring, C NP | |
|
1309 10th Ave W, Mobridge, SD 57601-1146 | |
| (605) 845-3692 | |
| (605) 845-8252 |
| Full Name | Candida Goehring |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 14 Years |
| Location | 1309 10th Ave W, Mobridge, South Dakota |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659683654 | NPI | - | NPPES |
| 1659683654 | Medicaid | SD | |
| S104312 | Other | PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | CP000592 (South Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mobridge Regional Hospital - Cah | Mobridge, SD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mobridge Regional Hospital | 6507776135 | 17 |
News Archive
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin.
A team of scientists from the Cedars-Sinai Regenerative Medicine Institute has been awarded a $1.9 million grant from the California Institute for Regenerative Medicine to fund development of a new technique to aid pharmaceutical discoveries for specific diseases.
New research presented at this week's ESCMID Conference on Coronavirus Disease (ECCVID, held online) shows that a shorter time from symptom onset to hospitalization is associated with more serious disease and death in patients with COVID-19.
To decide whether a new medical technology is cost effective, researchers often "compare a new technology's incremental cost-effectiveness ratio or ICER to a threshold that is some multiple of a country or income group's GDP per capita, per WHO convention," Amanda Glassman, director of global health policy and a senior fellow at the Center for Global Development (CGD), writes in the CGD's "Global Health Policy" blog
› Verified 7 days ago
| Entity Name | Mobridge Regional Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871554311 PECOS PAC ID: 6507776135 Enrollment ID: O20040130000772 |
News Archive
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin.
A team of scientists from the Cedars-Sinai Regenerative Medicine Institute has been awarded a $1.9 million grant from the California Institute for Regenerative Medicine to fund development of a new technique to aid pharmaceutical discoveries for specific diseases.
New research presented at this week's ESCMID Conference on Coronavirus Disease (ECCVID, held online) shows that a shorter time from symptom onset to hospitalization is associated with more serious disease and death in patients with COVID-19.
To decide whether a new medical technology is cost effective, researchers often "compare a new technology's incremental cost-effectiveness ratio or ICER to a threshold that is some multiple of a country or income group's GDP per capita, per WHO convention," Amanda Glassman, director of global health policy and a senior fellow at the Center for Global Development (CGD), writes in the CGD's "Global Health Policy" blog
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Candida Goehring, C NP Po Box 206, Timber Lake, SD 57656-0206 Ph: (605) 865-3258 | Candida Goehring, C NP 1309 10th Ave W, Mobridge, SD 57601-1146 Ph: (605) 845-3692 |
News Archive
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for under-served medical needs in neurology and cardiology, announced the completion of the interim analysis of the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA).
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin.
A team of scientists from the Cedars-Sinai Regenerative Medicine Institute has been awarded a $1.9 million grant from the California Institute for Regenerative Medicine to fund development of a new technique to aid pharmaceutical discoveries for specific diseases.
New research presented at this week's ESCMID Conference on Coronavirus Disease (ECCVID, held online) shows that a shorter time from symptom onset to hospitalization is associated with more serious disease and death in patients with COVID-19.
To decide whether a new medical technology is cost effective, researchers often "compare a new technology's incremental cost-effectiveness ratio or ICER to a threshold that is some multiple of a country or income group's GDP per capita, per WHO convention," Amanda Glassman, director of global health policy and a senior fellow at the Center for Global Development (CGD), writes in the CGD's "Global Health Policy" blog
› Verified 7 days ago
Karen Fryhling, Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 1309 10th Ave W, Mobridge, SD 57601 Phone: 605-845-3692 | |
Anette Hollenbeck, CNP Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 1401 10th Ave W, Mobridge, SD 57601 Phone: 605-848-0458 | |
Todd Salfrank, CNP Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 1309 10th Ave W, Mobridge, SD 57601 Phone: 605-845-3692 | |
Dorinda Vojta, CNM Nurse Practitioner Medicare: May Accept Medicare Assignments Practice Location: 1309 10th Ave W, Mobridge, SD 57601 Phone: 605-845-3692 Fax: 605-845-8252 |